A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy
| Autor: | Chang-Woo Lee, Sung Hak Chun, Ga-Young Park, Chang Geun Lee, Janet Lee, Jae Ho Lee, Jeong Yun Han, Kwangmo Yang, Yu Kyeong Han, Sung Dae Kim |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
CA15-3
Radiation-Sensitizing Agents medicine.medical_treatment Biophysics Apoptosis Breast Neoplasms Radiation Tolerance Biochemistry Targeted therapy Cell therapy Breast cancer Differentiation therapy Cancer stem cell medicine Humans Molecular Targeted Therapy Protein Kinase Inhibitors Molecular Biology business.industry Cyclin-Dependent Kinase 4 Cell Cycle Checkpoints Cell Biology medicine.disease Cancer cell Immunology Neoplastic Stem Cells Cancer research Female Stem cell business |
| Zdroj: | Biochemical and Biophysical Research Communications. 430:1329-1333 |
| ISSN: | 0006-291X |
| DOI: | 10.1016/j.bbrc.2012.10.119 |
| Popis: | Cancer stem cells (CSCs) are one of the main reasons behind cancer recurrence due to their resistance to conventional anti-cancer therapies. Thus, many efforts are being devoted to developing CSC-targeted therapies to overcome the resistance of CSCs to conventional anti-cancer therapies and decrease cancer recurrence. Differentiation therapy is one potential approach to achieve CSC-targeted therapies. This method involves inducing immature cancer cells with stem cell characteristics into more mature or differentiated cancer cells. In this study, we found that a CDK4 inhibitor sensitized MDA-MB-231 cells but not MCF7 cells to irradiation. This difference appeared to be associated with the relative percentage of CSC-population between the two breast cancer cells. The CDK4 inhibitor induced differentiation and reduced the cancer stem cell activity of MDA-MB-231 cells, which are shown by multiple marker or phenotypes of CSCs. Thus, these results suggest that radiosensitization effects may be caused by reducing the CSC-population of MDA-MB-231 through the use of the CDK4 inhibitor. Thus, further investigations into the possible application of the CDK4 inhibitor for CSC-targeted therapy should be performed to enhance the efficacy of radiotherapy for breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect